Physician profile
Puneet Basi
NPI 1730343120
$3,811.36
in general payments reported to CMS, 2019-2025
24 companies · $2,056 in 2025
The $2,056 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $18.01 · 2021: $111 · 2022: $17.65 · 2023: $734 · 2024: $595 · 2025: $2,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,809 · Consulting Fee: $550 · Education: $25.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,808.97 |
| Consulting Fee | $550.00 |
| Education | $25.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,527.51 | 2019-2025 | Rinvoq |
| Zoll Medical Corporation | $550.00 | 2023 | |
| Janssen Biotech, INC. | $264.40 | 2024-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $148.15 | 2024-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $138.15 | 2024-2025 | |
| Qol Medical, LLC | $138.09 | 2025 | Sucraid |
| Boston Scientific Corporation | $137.95 | 2019-2022 | |
| Ardelyx, INC. | $99.37 | 2024-2025 | Ibsrela |
| Insmed, INC. | $95.69 | 2019 | |
| Novo Nordisk INC | $90.25 | 2025 | Wegovy |
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Celltrion USA INC. | $75.90 | 2024-2025 | Vegzelma, Zymfentra |
| Micro-Tech Endoscopy USA, INC. | $66.87 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $63.77 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.33 | 2025 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $59.06 | 2023 | Endoflip |
| Lilly USA, LLC | $44.96 | 2025 | Omvoh |
| Merck Sharp & Dohme LLC | $33.24 | 2024 | Dificid |
| Pfizer INC. | $27.48 | 2019-2024 | |
| Madrigal Pharmaceuticals | $24.85 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $22.78 | 2025 | Injectafer |
| Aimmune Therapeutics, INC. | $21.64 | 2025 | Zenpep |
| Pharmacosmos Therapeutics INC. | $20.70 | 2024 | Monoferric |
| Phathom Pharmaceuticals, INC. | $16.22 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Basi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.